Roosevelt Investment Group Inc. bought a new position in Bristol-Myers Squibb Co (NYSE:BMY) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 3,369 shares of the biopharmaceutical company’s stock, valued at approximately $215,000.

Several other institutional investors have also bought and sold shares of BMY. Tradewinds Capital Management LLC increased its holdings in shares of Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 500 shares during the last quarter. Atlantic Trust LLC bought a new stake in shares of Bristol-Myers Squibb in the 2nd quarter worth about $111,000. Massey Quick Simon & CO. LLC increased its holdings in shares of Bristol-Myers Squibb by 523.5% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 1,492 shares during the last quarter. Blue Chip Partners Inc. increased its holdings in shares of Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 15 shares during the last quarter. Finally, BDO Wealth Advisors LLC bought a new stake in shares of Bristol-Myers Squibb in the 2nd quarter worth about $123,000. Hedge funds and other institutional investors own 69.74% of the company’s stock.

BMY has been the topic of a number of research reports. Vetr upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 target price on the stock in a report on Wednesday, September 27th. Jefferies Group restated a “buy” rating and issued a $72.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, September 27th. UBS Group restated a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 12th. Finally, Barclays lifted their price target on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Friday, October 13th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have given a buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $65.11.

Bristol-Myers Squibb Co (BMY) opened at $62.28 on Friday. Bristol-Myers Squibb Co has a 52 week low of $46.01 and a 52 week high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. The company has a market cap of $101,930.00, a PE ratio of 24.52, a P/E/G ratio of 2.14 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same period in the prior year, the firm posted $0.77 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 6.7% on a year-over-year basis. analysts predict that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 2.57%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s payout ratio is 62.99%.

In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the sale, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.watchlistnews.com/roosevelt-investment-group-inc-takes-215000-position-in-bristol-myers-squibb-co-bmy/1815359.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.